NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C

NCT01604291

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Hepatitis C, Chronic

Countries: Israel

This multi-center, observational study will evaluate the efficacy and safety of dual and triple therapies based on Pegasys (peginterferon alfa-2a) in patients with chronic hepatitis C. Patients receiving treatment with either Pegasys plus ribavirin or Pegasys plus ribavirin plus telaprevir/boceprevir will be observed for the duration of their treatment and for up to 24 weeks of follow-up.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Adult patients, \>/= 18 years of age
* Chronic hepatitis C (all genotypes, naïve or treatment experienced, HCV mono-infected or HCV-HIV co-infected)
* Receiving either dual therapy (Pegasys plus ribavirin) or triple therapy (Pegasys plus ribavirin plus telaprevir/boceprevir)
* No contra-indications to Pegasys and ribavirin therapy or to treatment regimen containing protease inhibitor (telaprevir or boceprevir) as detailed in local Prescribing Information
* Quantitative serum HCV RNA by PCR test before initiation of treatment

Exclusion Criteria:

* Hepatitis A/B co-infection
* Evidence of severe illness, active malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
* Pregnant or breast-feeding women

Locations (21)

Afula, Israel
Ashkelon, Israel
Beersheba, Israel
Hadera, Israel
Haifa, Israel
Haifa, Israel
Haifa, Israel
Holon, Israel
Jerusalem, Israel
Jerusalem, Israel
Kfar Saba, Israel
Nahariya, Israel
Nazareth, Israel
Petah Tikva, Israel
Petah Tikva, Israel
Ramat Gan, Israel
Rehovot, Israel
Safed, Israel
Tel Aviv, Israel
Tiberias, Israel
Ẕerifin, Israel